Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AVROBIO stock | 16.22

Own AVROBIO stock in just a few minutes.

Posted

Fact checked

AVROBIO, Inc is a biotechnology business based in the US. AVROBIO shares (AVRO) are listed on the NASDAQ and all prices are listed in US Dollars. AVROBIO employs 121 staff and has a market cap (total outstanding shares value) of USD$571.4 million.

How to buy shares in AVROBIO

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AVROBIO. Find the stock by name or ticker symbol: AVRO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AVROBIO reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$16.22, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of AVROBIO, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AVROBIO. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted AVROBIO's share price?

Since the stock market crash in March caused by coronavirus, AVROBIO's share price has had significant negative movement.

Its last market close was USD$16.22, which is 28.70% down on its pre-crash value of USD$22.75 and 66.19% up on the lowest point reached during the March crash when the shares fell as low as USD$9.76.

If you had bought USD$1,000 worth of AVROBIO shares at the start of February 2020, those shares would have been worth USD$712.74 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$803.38.

AVROBIO share price

Use our graph to track the performance of AVRO stocks over time.

AVROBIO shares at a glance

Information last updated 2020-10-19.
Latest market close USD$16.22
52-week range USD$9.76 - USD$28.44
50-day moving average USD$15.1044
200-day moving average USD$16.7925
Wall St. target price USD$37.71
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.536

Buy AVROBIO shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AVROBIO stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AVROBIO price performance over time

Historical closes compared with the close of $16.22 from 2020-11-16

1 week (2020-11-17) -0.86%
1 month (2020-10-23) -2.76%
3 months (2020-08-25) -4.53%
6 months (2020-05-23) N/A
1 year (2019-11-25) 1.19%
2 years (2018-11-23) -34.46%
3 years (2017-11-23) N/A
5 years (2015-11-23) N/A

AVROBIO financials

Gross profit TTM USD$0
Return on assets TTM -33.89%
Return on equity TTM -56.92%
Profit margin 0%
Book value $6.582
Market capitalisation USD$571.4 million

TTM: trailing 12 months

Shorting AVROBIO shares

There are currently 3.2 million AVROBIO shares held short by investors – that's known as AVROBIO's "short interest". This figure is 14.4% up from 2.8 million last month.

There are a few different ways that this level of interest in shorting AVROBIO shares can be evaluated.

AVROBIO's "short interest ratio" (SIR)

AVROBIO's "short interest ratio" (SIR) is the quantity of AVROBIO shares currently shorted divided by the average quantity of AVROBIO shares traded daily (recently around 196181.74019608). AVROBIO's SIR currently stands at 16.32. In other words for every 100,000 AVROBIO shares traded daily on the market, roughly 16320 shares are currently held short.

However AVROBIO's short interest can also be evaluated against the total number of AVROBIO shares, or, against the total number of tradable AVROBIO shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AVROBIO's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 AVROBIO shares in existence, roughly 90 shares are currently held short) or 0.1033% of the tradable shares (for every 100,000 tradable AVROBIO shares, roughly 103 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against AVROBIO.

Find out more about how you can short AVROBIO stock.

AVROBIO share dividends

We're not expecting AVROBIO to pay a dividend over the next 12 months.

AVROBIO share price volatility

Over the last 12 months, AVROBIO's shares have ranged in value from as little as $9.76 up to $28.44. A popular way to gauge a stock's volatility is its "beta".

AVRO.US volatility(beta: 1.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVROBIO's is 1.6847. This would suggest that AVROBIO's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

AVROBIO overview

AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site